Compare ATEC & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATEC | OGN |
|---|---|---|
| Founded | 1990 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2006 | 2020 |
| Metric | ATEC | OGN |
|---|---|---|
| Price | $8.28 | $13.44 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 5 |
| Target Price | ★ $22.00 | $11.40 |
| AVG Volume (30 Days) | 2.3M | ★ 2.6M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.60% |
| EPS Growth | ★ 15.04 | N/A |
| EPS | N/A | ★ 0.55 |
| Revenue | $101,739,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $18.97 | $0.45 |
| Revenue Next Year | $16.70 | $1.67 |
| P/E Ratio | ★ N/A | $24.45 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.82 | $5.69 |
| 52 Week High | $23.29 | $13.49 |
| Indicator | ATEC | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 49.25 | 73.96 |
| Support Level | $7.27 | $10.05 |
| Resistance Level | $8.42 | $13.46 |
| Average True Range (ATR) | 0.38 | 0.05 |
| MACD | 0.16 | -0.14 |
| Stochastic Oscillator | 90.58 | 75.00 |
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.